VivoSeq
Other

Endometritis

12

Pipeline Programs

4

Active Trials

4

Companies Involved

Endometritis is an emerging landscape with 12 programs across 4 companies. The most active players are Pfizer, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 4 therapies are approved.

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

6/100

Mech. Concentration

40/100

Completion Rate

88/100

Attrition Rate

7/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

14

clinical trials

Completed7 · 50%
Not yet recruiting2 · 14%
Unknown status2 · 14%
Recruiting2 · 14%
Withdrawn1 · 7%

Trial Activity

14 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)